Login to Your Account

Sorrento drafts broad global strategy, reports positive trial for Xolair biosimilar in China

By Shannon Ellis
Staff Writer

Friday, May 20, 2016

SHANGHAI – Sorrento Therapeutics Inc. reported that STI-004 proved to be safe and efficacious in both adult and adolescent patients suffering from allergic asthma when compared to placebo, successfully completing a combined phase II/III study in China.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription